Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:00:41 31/05/2024 pm IST			5-day change	1st Jan Change
231 ^CHF	+1.18%		+0.26%	-5.52%

31/05	ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	ZD
31/05	Transcript : Roche Holding AG - Shareholder/Analyst Call

ROCHE HOLDINGS AG : Deutsche Bank Upgrades to Neutral

May 17, 2024 at 12:55 pm IST

Deutsche Bank readjusts its opinion and goes from selling to neutral on the stock. The target price is unchanged and still at CHF 215.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	01/06	ZD
Transcript : Roche Holding AG - Shareholder/Analyst Call	31/05
ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating	30/05	ZD
Swiss Stocks Fall as Rate Jitters Intensify Amid Latest Inflation Data	29/05	MT
Global markets live: BHP, Anglo American, Lenovo, Nvidia, Apple...	29/05
European Midday Briefing : Mood Sours as Fed Rate-Cut Bets Curtailed	29/05	DJ
Roche: FDA grants priority review in breast cancer	29/05	CF
Roche's Metastatic Breast Cancer Treatment Granted Priority Review by US FDA	29/05	MT
Roche Breast-Cancer Drug Gets Priority Review in the U.S.	29/05	DJ
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant	29/05	CI
Roche renews diagnostic partnership with Hitachi	27/05	CF
Roche appoints Director of Corporate Business Development	27/05	CF
Roche and Hitachi High-Tech Extend Their 46-Year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing	27/05	CI
Roche Announces Management and Board Committee Changes	27/05	CI
Swiss Market Index Slumps as Economic Data Triggers Rate Jitters Anew	24/05	MT
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	24/05	ZD
UK Watchdog Launches Probe into Roche's LumiraDx Purchase	24/05	MT
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog	24/05	DJ
Transcript : Roche Holding AG - Analyst/Investor Day	22/05
Roche: FDA designation for blood test	22/05	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	22/05	MT
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)	22/05	CI
Europe stock pickers go old-school to ride the next wave in AI	22/05	RE
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson...	21/05
Roche: Breakthrough designation for inavolisib in breast cancer	21/05	CF

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

231 CHF

Average target price

277.5 CHF

Spread / Average Target

+20.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-5.52%	21TCr
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
AMGEN INC.	+6.17%	16TCr
PFIZER, INC.	-0.45%	16TCr
SANOFI	-.--%	12TCr

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Deutsche Bank Upgrades to Neutral

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals